- Home
- SWKH vs FENC Comparison
SWKH vs FENC Comparison
Compare SWKH & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWKH | FENC |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Diversified Financial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SWKH | FENC |
|---|---|---|
| Price | $16.70 | $9.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $14.50 |
| AVG Volume (30 Days) | 104.8K | ★ 270.7K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | $9.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.86 | $5.65 |
| 52 Week High | $17.90 | $10.27 |
Technical Indicators
Market Signals| Indicator | SWKH | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 32.19 | 76.29 |
| Support Level | $14.69 | $7.45 |
| Resistance Level | $17.08 | $9.92 |
| Average True Range (ATR) | 0.37 | 0.65 |
| MACD | -0.05 | 0.30 |
| Stochastic Oscillator | 12.06 | 85.82 |
Price Performance
Historical ComparisonAbout SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.